Recently, Wang and co-workers [265] designed and synthesized a series of cyclin-dependent kinase 9 (CDK9) inhibitors with cancer stem cell (CSC) inhibition activity for non-small-cell lung cancer (NSCLC) therapy. The gene discussed is CDK9; the disease is non-small cell lung carcinoma.